UPCC 08823 Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease - PATROL

Detecting Prostate Cancer Early in Individuals with Genetic Risk

Enrolling By Invitation
40 years or above
Male
Phase N/A
450 participants needed
1 Location

Brief description of study

This study investigates ways to detect prostate cancer earlier in people at genetic risk for disease that forms, grows, or spreads quickly (aggressive). Studying samples of blood, urine, and/or tissue in the laboratory may help doctors further understand the genetics of prostate cancer and help identify ways to detect cancer earlier, thereby improving treatment and methods of early detection in the future.

Detailed description of study

OUTLINE

Participants undergo collection of blood, urine, and/or tissue samples every 6-12 months, when any biopsy occurs, and if relevant, at time of curative therapy and 3-9 months after completion of curative therapy for up to 3 years.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Prostate Carcinoma
  • Age: 40 years or above
  • Gender: Male

Inclusion Criteria:

  • People with prostates ≥40 years of age
  • Documented germline pathogenic variant in known or suspected genes associated with prostate cancer risk.

Exclusion Criteria:

  • Prior diagnosis of prostate cancer
  • Medical contraindication to any of the study procedures (e.g., prostate biopsy)
  • For all cancer types except non-melanoma skin cancer, any cancer treatment with curative intent within the past 12 months (e.g., surgery, radiation, chemotherapy, immunotherapy)
  • Prior or concurrent participation in an interventional clinical trial aimed at preventing cancer for people with germline variants associated with increased prostate cancer risk
  • Unable to provide written informed consent
  • Unable or unwilling to complete clinical care and study procedures as indicated by the study protocol.

This study investigates ways to detect prostate cancer earlier in people at genetic risk for aggressive disease, which forms, grows, or spreads quickly. The purpose is to study samples of blood, urine, and tissue in the laboratory to better understand the genetics of prostate cancer. This research aims to identify ways to detect cancer earlier, potentially improving future treatment and methods of early detection.

Participants will have blood, urine, and/or tissue samples collected every 6-12 months, during any biopsy, and at the time of and following curative therapy. These procedures will be carried out for up to 3 years to gather data for analysis.

  • Who can participate: People with prostates aged 40 years and older who have a documented germline pathogenic variant associated with prostate cancer risk can participate. Individuals with a prior diagnosis of prostate cancer or those who have had cancer treatment with curative intent within the past 12 months are excluded.
  • Study details: Participants will provide blood, urine, and tissue samples regularly and during specific medical events. These samples will help researchers study the genetics of prostate cancer. Participants must be able to consent and adhere to study procedures.
  • Study timelines: The study will last up to 3 years.
Updated on 15 May 2026. Study ID: 23-0752
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Abramson Cancer Center Navigator